Travere Therapeutics Inc.

02/12/2025 | Press release | Distributed by Public on 02/12/2025 20:27

Statement of Changes in Beneficial Ownership (Form 4)

FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Calvin Sandra
2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [TVTX] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
SVP, CHIEF ACCOUNTING OFFICER
(Last) (First) (Middle)
C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300 		3. Date of Earliest Transaction (Month/Day/Year)
02/11/2025
(Street)
SAN DIEGO, CA 92130 		4. If Amendment, Date Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) 		7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/11/2025 M 10,000 A $16.23 73,654 D
Common Stock 02/11/2025 S(1) 10,000 D $25 63,654 D
Common Stock 02/11/2025 M 10,000 A $17.44 73,654 D
Common Stock 02/11/2025 S(2) 10,000 D $25 63,654 D
Common Stock 02/11/2025 M 10,000 A $17.96 73,654 D
Common Stock 02/11/2025 S(3) 10,000 D $25 63,654 D
Common Stock 02/11/2025 M 15,000 A $15.46 78,654 D
Common Stock 02/11/2025 S(4) 15,000 D $25 63,654 D
Common Stock 02/11/2025 S(5) 9,244 D $25 54,410 D
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5) 		6. Date Exercisable and Expiration Date
(Month/Day/Year) 		7. Title and Amount of Underlying Securities
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4) 		10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4) 		11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Employee stock option (right to buy) $16.23 02/11/2025 M 10,000 (6) 05/19/2026 Common Stock 10,000 $ 0 0 D
Employee stock option (right to buy) $17.44 02/11/2025 M 10,000 (6) 05/17/2027 Common Stock 10,000 $ 0 0 D
Employee stock option (right to buy) $17.96 02/11/2025 M 10,000 (6) 05/09/2029 Common Stock 10,000 $ 0 0 D
Employee stock option (right to buy) $15.46 02/11/2025 M 15,000 (6) 01/31/2030 Common Stock 15,000 $ 0 0 D

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Calvin Sandra
C/O TRAVERE THERAPEUTICS, INC.
3611 VALLEY CENTRE DRIVE, SUITE 300
SAN DIEGO, CA 92130 		SVP, CHIEF ACCOUNTING OFFICER

Signatures

/s/ Elizabeth E. Reed, Attorney-in-Fact 02/12/2025
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 19, 2016 with an expiration date of May 19, 2026.
(2) This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 17, 2017 with an expiration date of May 17, 2027.
(3) This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 9, 2019 with an expiration date of May 9, 2029.
(4) This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 31, 2020 with an expiration date of January 31, 2030.
(5) This sale was made pursuant to a written plan adopted on September 9, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.
(6) The stock option is fully vested and exercisable.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.